Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
GAITHERSBURG, Md., Sept. 07, 2016 -- OpGen, Inc. (NASDAQ:OPGN) an informatics and genomic analysis company, announces that Evan Jones, the Company’s Chairman and Chief Executive Officer, will provide a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference. Mr. Jones’ presentation will be on Monday, September 12, 2016 at 3:25 p.m. Eastern time. The conference is being held from September 11 to 13 in New York City.
To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.’s website at www.opgen.com. An archived audio of the presentation will also be available on OpGen’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contacts:
OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
[email protected]
[email protected]
Investor Relations
LHA
Kim Sutton Golodetz
(212) 838-3777
[email protected]
Bruce Voss
(310) 691-7100
[email protected]
OpGen Media
MacDougall Biomedical Communications
Cammy Duong
(781) 235-3060
[email protected]
